| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.007 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.087 | 0.009 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.009 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.009 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.089 | 0.01 |
| mRNA | bendamustine | CTRPv2 | pan-cancer | AAC | -0.099 | 0.01 |